Stockwatch: When JnJ Speaks, Others Copy
This article was originally published in Scrip
In David Thomas' 2011 novel Blood Relative, a husband tries to recreate his wife's life in the heart of the former German Democratic Republic as a time when the influence of the socialist state was absolute. In a similar way, but in the home of capitalism, the world's largest healthcare company Johnson & Johnson (J&J) reported its third-quarter earnings last week and its methods to massage the news quickly influenced announcements of much smaller companies.
You may also be interested in...
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.
With something for everyone in Johnson & Johnson’s second-quarter earnings report, a nudge upwards for full-year guidance could not disguise the jump down from January’s pre-pandemic expectations.